Cube Biotech and IBA Lifesciences, two leading innovators in the biotechnology industry, join forces to create a unified powerhouse dedicated to advancing research and production capabilities for the life science industry.

The combined entity will leverage its complementary strengths to deliver unparalleled solutions in protein purification and stabilization and to enable groundbreaking research in the field of challenging drug targets. The acquisition will translate into enhanced product portfolio, global reach, innovative R&D synergy and customer-centric solutions.

Cube Biotech's vision to accelerate innovation, simplify services, and broaden its global presence is reflected in the acquisition. Over the course of the last 12 months, the company has formed multiple collaborations to realize these goals. By combining Cube Biotech’s expertise in protein technologies with IBA Lifesciences strength in high performance research tools for protein isolation and analysis, the new entity is uniquely positioned to address the evolving needs of researchers and industry professionals worldwide.

Didier Dargent, CEO of Cube Biotech, stated, “This acquisition marks an exciting new chapter for both companies. Together, we will harness our collective expertise to push the boundaries of what’s possible in the life sciences and enable researchers to make groundbreaking discoveries.”

Mike Rothe, CEO of IBA Lifesciences, added, “The fusion of our technologies and talents creates an outstanding foundation for innovation. Our combined efforts will benefit our customers and strengthen our position as leaders in the biotechnology market.”